This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000556
First received: October 27, 1999
Last updated: March 24, 2016
Last verified: November 2005
  Purpose
To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.

Condition Intervention Phase
Arrhythmia Atrial Fibrillation Cardiovascular Diseases Heart Diseases Drug: amiodarone Drug: sotalol Drug: propafenone Drug: flecainide Drug: quinidine Drug: moricizine Drug: disopyramide Drug: procainamide Drug: adrenergic beta antagonists Drug: verapamil Drug: diltiazem Drug: digoxin Procedure: catheter ablation Device: pacemaker, artificial Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: March 1995
Estimated Study Completion Date: September 2002
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   65 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Elderly men and women with atrial fibrillation and other risk factors for stroke.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000556

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
OverallOfficial: H. Greene Statistics and Epidemiology Research Corporation (S.E.R.C.)
  More Information

Publications:

Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Identifier: AFFIRM
NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00000556     History of Changes
Other Study ID Numbers: 100
Study First Received: October 27, 1999
Last Updated: March 24, 2016

Additional relevant MeSH terms:
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Arrhythmias, Cardiac
Pathologic Processes
Digoxin
Amiodarone
Verapamil
Flecainide
Quinidine
Sotalol
Propafenone
Procainamide
Disopyramide
Moricizine
Diltiazem
Adrenergic Agents
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Cardiotonic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Vasodilator Agents
Potassium Channel Blockers
Membrane Transport Modulators
Sodium Channel Blockers
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 23, 2017